Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia.
about
Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug developmentIs adiposopathy (sick fat) an endocrine disease?New obesity classification criteria as a tool for bariatric surgery indicationGLUT4 defects in adipose tissue are early signs of metabolic alterations in Alms1GT/GT, a mouse model for obesity and insulin resistanceThe relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveysBariatric endocrinology: principles of medical practice.Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything.Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes.Reduced cardiovascular risk following bariatric surgeries is related to a partial recovery from "adiposopathy"Torcetrapib/atorvastatin combination therapy.Adipose tissue dysfunction in humans: a potential role for the transmembrane protein ENPP1.Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factorsImpact of uremia on human adipose tissue phenotype.Preoperative diet impacts the adipose tissue response to surgical trauma.Inflammatory "adiposopathy" in major amputation patients.Origins of metabolic complications in obesity: adipose tissue and free fatty acid trafficking.Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity.Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease?Adiposopathy, "sick fat," Ockham's razor, and resolution of the obesity paradox.Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.Obesity and type 2 diabetes: which patients are at risk?Adiposopathy and thyroid disease: tracing the pathway to cardiovascular risk.The role of adiponectin in endothelial dysfunction and hypertension.Adipocyte maturation arrest: a determinant of systemic insulin resistance to glucose disposalAdherence to the Baltic Sea diet consumed in the Nordic countries is associated with lower abdominal obesity.Macroscopic anatomic changes of subcutaneous fat tissue in massive-weight-loss patients.Fitness, adiposopathy, and adiposity are independent predictors of insulin sensitivity in middle-aged men without diabetes.Adiposopathy: why do adiposity and obesity cause metabolic disease?A Network Biology Approach for Assessing the Role of Pathologic Adipose Tissues in Insulin Resistance Using Meta-analysis of Microarray Datasets
P2860
Q22241480-CC986E46-77EE-4235-8B0F-094A647F6C70Q24655610-28D1EC81-C270-46CB-8BC1-9880F2D231F6Q26774656-3CFA2BC5-44E0-4EE6-96BE-BDE9B2250E20Q27339452-3CE5C765-E2C6-457A-81E3-B8530D9DD2DAQ31112204-E8B99046-8319-476C-A6E5-6F44BE9BAE6FQ33677790-32A5D231-A01A-4080-B76B-B274291CB969Q34418386-200906C5-5ECD-459B-A43B-99FD3F4DCAEAQ34591803-36C8CB71-1264-4AE6-A239-5F5B9313BF57Q34659424-D8A2C36C-69F3-4856-ACC2-86F77A05A005Q35126491-46BF7DC4-A106-4708-BE22-2A3639E9E191Q35190566-B9E95B0E-B67F-4D14-B67A-344186CC3549Q36265996-540D80A1-D323-4C42-8162-B7421DB43279Q36442413-9AE3E15E-D529-44FF-A93C-6ED1F4E9BD44Q36536210-80E1F249-E5EE-46EB-9DCC-F8FF2699C6D0Q36637146-A46F8A96-596F-4234-AFA0-3ADE661E5745Q36702089-24AAE294-718A-47F0-AA72-F8BCAD7367C5Q36702097-26D48FC9-0408-48D9-AA02-40F14B81A4A7Q37013861-143924DF-C935-47E8-8849-E5C83BFE7E23Q37104877-F8395F1E-255D-47A1-8608-FDD3D8D741F5Q37323375-4FF86A84-DA88-4A5B-B832-A206A0051493Q37427308-97A8F16D-5193-4F23-82D3-9C21F49AAC52Q37678834-51274D05-6940-4556-895B-A5BB2A07210DQ37779809-4E7CFE39-5115-4C4D-8056-E3BA53C099C2Q37954693-014E5838-0837-4754-8D1C-B18A08F8FE22Q38034811-E313E0FD-65AB-4B8B-843A-382F4CA2106CQ38219891-45E0CC26-CADE-4DCE-8B64-12BBD92757E6Q42557648-6C216F48-0E7A-4FCF-B26B-66519460D5B0Q43949379-B8E846D6-E382-4CCC-A80E-51A521D4DDFBQ47382998-C0B8654E-6547-4999-A5E1-0ECF24E7C77AQ53787695-01360FDC-4318-4794-8777-74DA6162F727Q56567724-E2B165BF-AF39-41FF-BEA3-25479DC1E1F7Q58549180-14394867-CA95-41F3-9E47-40687E5A31EF
P2860
Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia.
@ast
Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia.
@en
type
label
Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia.
@ast
Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia.
@en
prefLabel
Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia.
@ast
Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia.
@en
P2093
P2860
P356
P1433
P1476
Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia.
@en
P2093
Harold Bays
Manisha Chandalia
Nicola Abate
P2860
P356
10.1517/14796678.1.1.39
P577
2005-01-01T00:00:00Z